280 related articles for article (PubMed ID: 33822485)
1. PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction.
Bolleddula J; Ke A; Yang H; Prakash C
CPT Pharmacometrics Syst Pharmacol; 2021 Jun; 10(6):577-588. PubMed ID: 33822485
[TBL] [Abstract][Full Text] [Related]
2. Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia.
Prakash C; Fan B; Ke A; Le K; Yang H
Cancer Chemother Pharmacol; 2020 Nov; 86(5):619-632. PubMed ID: 32978634
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetic and exposure-response analyses of ivosidenib in patients with IDH1-mutant advanced hematologic malignancies.
Jiang X; Wada R; Poland B; Kleijn HJ; Fan B; Liu G; Liu H; Kapsalis S; Yang H; Le K
Clin Transl Sci; 2021 May; 14(3):942-953. PubMed ID: 33493392
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies.
Chen Y; Nagaraja NV; Fan B; Utley L; Lemieux RM; Popovici-Muller J; Dang L; Kim H; Yan L; Su SM; Biller SA; Yang H
Drug Metab Dispos; 2021 Oct; 49(10):870-881. PubMed ID: 34321251
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation.
Fan B; Dai D; DiNardo CD; Stein E; de Botton S; Attar EC; Liu H; Liu G; Lemieux I; Agresta SV; Yang H
Cancer Chemother Pharmacol; 2020 May; 85(5):959-968. PubMed ID: 32296873
[TBL] [Abstract][Full Text] [Related]
6. Physiologically based pharmacokinetic modeling to assess metabolic drug-drug interaction risks and inform the drug label for fedratinib.
Wu F; Krishna G; Surapaneni S
Cancer Chemother Pharmacol; 2020 Oct; 86(4):461-473. PubMed ID: 32886148
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors.
Fan B; Mellinghoff IK; Wen PY; Lowery MA; Goyal L; Tap WD; Pandya SS; Manyak E; Jiang L; Liu G; Nimkar T; Gliser C; Prahl Judge M; Agresta S; Yang H; Dai D
Invest New Drugs; 2020 Apr; 38(2):433-444. PubMed ID: 31028664
[TBL] [Abstract][Full Text] [Related]
8. Application of a "Fit for Purpose" PBPK Model to Investigate the CYP3A4 Induction Potential of Enzalutamide.
Narayanan R; Hoffmann M; Kumar G; Surapaneni S
Drug Metab Lett; 2016; 10(3):172-179. PubMed ID: 27604990
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms and Predictions of Drug-Drug Interactions of the Hepatitis C Virus Three Direct-Acting Antiviral Regimen: Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir.
Shebley M; Liu J; Kavetskaia O; Sydor J; de Morais SM; Fischer V; Nijsen MJMA; Bow DAJ
Drug Metab Dispos; 2017 Jul; 45(7):755-764. PubMed ID: 28483778
[TBL] [Abstract][Full Text] [Related]
10. Effect of itraconazole, food, and ethnic origin on the pharmacokinetics of ivosidenib in healthy subjects.
Dai D; Yang H; Nabhan S; Liu H; Hickman D; Liu G; Zacher J; Vutikullird A; Prakash C; Agresta S; Bowden C; Fan B
Eur J Clin Pharmacol; 2019 Aug; 75(8):1099-1108. PubMed ID: 31011758
[TBL] [Abstract][Full Text] [Related]
11. Clinical assessment of momelotinib drug-drug interactions via CYP3A metabolism and transporters.
Ho YL; Gorycki P; Ferron-Brady G; Martin P; Vlasakakis G
Clin Transl Sci; 2024 Apr; 17(4):e13799. PubMed ID: 38634429
[TBL] [Abstract][Full Text] [Related]
12. Creation of Novel Sensitive Probe Substrate and Moderate Inhibitor Models for a Comprehensive Prediction of CYP2C8 Interactions for Tucatinib.
Templeton IE; Rowland-Yeo K; Jones HM; Endres CJ; Topletz-Erickson AR; Sun H; Lee AJ
Clin Pharmacol Ther; 2024 Feb; 115(2):299-308. PubMed ID: 37971208
[TBL] [Abstract][Full Text] [Related]
13. Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model.
Freise KJ; Shebley M; Salem AH
J Clin Pharmacol; 2017 Jun; 57(6):796-804. PubMed ID: 28052338
[TBL] [Abstract][Full Text] [Related]
14. Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions.
Hanke N; Gómez-Mantilla JD; Ishiguro N; Stopfer P; Nock V
Pharm Res; 2021 Oct; 38(10):1645-1661. PubMed ID: 34664206
[TBL] [Abstract][Full Text] [Related]
15. Quantitative Assessment of Elagolix Enzyme-Transporter Interplay and Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling.
Chiney MS; Ng J; Gibbs JP; Shebley M
Clin Pharmacokinet; 2020 May; 59(5):617-627. PubMed ID: 31713224
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Safety and Clinically Relevant Drug-Drug Interactions with Tucatinib in Healthy Volunteers.
Topletz-Erickson A; Lee A; Rustia EL; Sun H; Mayor JG; Abdulrasool LI; Walker L; Endres CJ
Clin Pharmacokinet; 2022 Oct; 61(10):1417-1426. PubMed ID: 35931943
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the Potential for Cytochrome P450 and Transporter-Mediated Drug-Drug Interactions for Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor (FXR) Agonist.
Younis I; Weber E; Nelson C; Kirby BJ; Shen G; Xiao D; Watkins TR; Othman AA
Clin Pharmacokinet; 2023 Apr; 62(4):609-621. PubMed ID: 36906733
[TBL] [Abstract][Full Text] [Related]
18. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
DiNardo CD; Stein EM; de Botton S; Roboz GJ; Altman JK; Mims AS; Swords R; Collins RH; Mannis GN; Pollyea DA; Donnellan W; Fathi AT; Pigneux A; Erba HP; Prince GT; Stein AS; Uy GL; Foran JM; Traer E; Stuart RK; Arellano ML; Slack JL; Sekeres MA; Willekens C; Choe S; Wang H; Zhang V; Yen KE; Kapsalis SM; Yang H; Dai D; Fan B; Goldwasser M; Liu H; Agresta S; Wu B; Attar EC; Tallman MS; Stone RM; Kantarjian HM
N Engl J Med; 2018 Jun; 378(25):2386-2398. PubMed ID: 29860938
[TBL] [Abstract][Full Text] [Related]
19. Ivosidenib: First Global Approval.
Dhillon S
Drugs; 2018 Sep; 78(14):1509-1516. PubMed ID: 30209701
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the Effects of Repeat-Dose Dabrafenib on the Single-Dose Pharmacokinetics of Rosuvastatin (OATP1B1/1B3 Substrate) and Midazolam (CYP3A4 Substrate).
Nebot N; Won CS; Moreno V; Muñoz-Couselo E; Lee DY; Gasal E; Bouillaud E
Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1054-1063. PubMed ID: 33932130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
